Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK586529 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving treatment in cohort 1 | EXPERIMENTAL | Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5). |
| Subjects receiving treatment in cohort 2 | EXPERIMENTAL | Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6) |
| Name | Type | Description |
|---|---|---|
| GSK586529 capsules | DRUG | GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams. |
| GSK586529 tablets | DRUG | GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams. |
| Placebo | DRUG | Placebo tablets and capsules will be provided to subjects. |
Inclusion Criteria: * Healthy males aged 18-45 years, inclusive. * Healthy subjects, defined as individuals who are free from clinically significant illness or disease as determined by their (and familial) medical and psychiatric history, physical examination, laboratory studies, and other tests. *...
GSK586529 is an investigational small molecule being developed for the treatment of Depressive Disorder and Anxiety Disorders. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its potential effects on these psychiatric conditions.
GSK586529 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in healthy volunteers.
GSK586529 is in Phase 1 clinical development. A first-in-human study has been completed, involving 21 healthy male volunteers in the United Kingdom. The drug is still investigational and has not received approval from regulatory agencies for any indication.
GSK586529 has one completed Phase 1 clinical trial registered as NCT00703547, titled 'A First Time in Human Study of GSK586529 in Healthy Volunteers.' This controlled study enrolled 21 healthy male participants aged 18 years and older in the United Kingdom.
GSK586529 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial was a first-in-human study in healthy volunteers, and the drug has not yet progressed to later-stage trials or received marketing authorization.